Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/29398
Title: Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial
Authors: BERWANGER, OtavioNICOLAU, Jose C.CARVALHO, Antonio C.JIANG, LixinGOODMAN, ShaunNICHOLLS, Stephen J.PARKHOMENKO, AlexanderAVERKOV, OlegTAJER, CarlosMALAGA, GermanSARAIVA, Jose F. KerrFONSECA, FranciscoGUIMARAES, Helio P.SILVA, Pedro G. M. de Barros eDAMIANI, Lucas P.PAISANI, Denise M.LASAGNO, Camila M. R.CANDIDO, Carolina T.VALEIS, NanciMOIA, Diogo D. F.PIEGAS, Leopoldo S.GRANGER, Christopher B.WHITE, HarveyLOPES, Renato D.
Citation: AMERICAN HEART JOURNAL, v.202, p.89-96, 2018
Abstract: Background: The safety and efficacy of ticagrelor in patients with ST-elevation myocardial infarction (STEMI) treated with fibrinolytic therapy remain uncertain. Objectives: The primary objective of the TicagRElor in pAtients with ST-elevation myocardial infarction treated with Thrombolysis (TREAT) trial is to evaluate the short-term safety of ticagrelor when compared with clopidogrel in STEMI patients treated with fibrinolytic therapy. Key secondary objectives are to assess the safety and efficacy of ticagrelor compared with clopidogrel at 12-months. Design: The TREAT trial is a multicenter, randomized, phase III, Prospective randomized open blinded end-point (PROBE) study that enrolled 3,799 patients in 152 sites from 10 countries. Following administration of fibrinolytic therapy patients were randomized to a loading dose of ticagrelor 180 mg or clopidogrel 300 mg followed by a maintenance dose of ticagrelor 90 mg twice daily or clopidogrel 75 mg/day for 12-months. The primary outcome is the rate of TIMI major bleeding at 30-days and will be assessed for non-inferiority using an intention-to-treat analysis. Co-treatments include aspirin and anticoagulants. Other evidence based therapies are also recommended. Secondary efficacy outcome include a composite of death from vascular causes, myocardial infarction, stroke, severe recurrent ischemia, transient ischemic attack or other arterial thrombotic event. All-cause mortality as well as individual components of the combined efficacy endpoint will also be ascertained. Summary: TREAT is an international randomized controlled trial comparing ticagrelor with clopidogrel in STEMI patients treated with fibrinolytic therapy. The results of this trial will inform clinical practice and international guidelines.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCP
Departamento de Cardio-Pneumologia - FM/MCP

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor

Artigos e Materiais de Revistas Científicas - LIM/11
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_BERWANGER_Ticagrelor_versus_clopidogrel_after_fibrinolytic_therapy_in_patients_2018.PDF
  Restricted Access
publishedVersion (English)649.29 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.